Cellectar Biosciences dismisses Baker Tilly, hires Deloitte; cites material weaknesses

Cellectar Biosciences, Inc.

Audit Committee dismissed Baker Tilly and is engaging Deloitte & Touche as independent auditor for FY2024, subject to standard procedures.
Baker Tilly's prior reports contained a going-concern emphasis paragraph; no disagreements except disclosed material weaknesses.
Material weaknesses identified: fair value methodologies for Level 3 instruments, stock-based compensation controls, and segregation of duties/user access.
No prior consultations with Deloitte on accounting principles or disagreements during fiscal years 2022-2023 and interim 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.